🟢 Beam Therapeutics Inc is trading 4% up today after FDA clearance for its PKU gene-editing trial

Beam Therapeutics Inc is trading at $33.78 (+4.00%) after the FDA cleared its Investigational New Drug (IND) application for BEAM-304, a base-editing candidate for the treatment of phenylketonuria (PKU).

• The regulatory clearance allows the company to initiate a Phase 1/2 clinical trial to evaluate the safety and efficacy of the gene-editing therapy.
• The stock is also benefiting from a broadly stronger market, with major U.S. indices trading higher and biotech sentiment bolstered by the regulatory win.